Paul Romesser is an Oncology physician affiliated with Memorial Sloan Kettering Cancer Center. OpenAlex indexes 314 publications with 10,500 citations (h-index 36); ClinicalTrials.gov lists 2 registered studies matched to this name.
Overview
Scholarship
indexed output and impact (OpenAlex)Distinct works indexed by OpenAlex, matched via ORCID.
Total citations across indexed works.
Hirsch index, productivity × impact (OpenAlex).
Clinical & industry
trials, payments and federal fundingContact
The practice address and phone this provider lists in the federal NPPES (CMS) registry.
Practice address
1275 York Ave
New York, NY 100656007
Telephone
212-639-2000Registry record last updated 20 Aug 2012.
Clinical trials
- A Study of Response to Standard Treatment Before Surgery in People With Rectal Cancer
Sponsor: Memorial Sloan Kettering Cancer Center
- A Study of Targeted Radiation Therapy in People With Non-Small Cell Lung Cancer (NSCLC)
Sponsor: Memorial Sloan Kettering Cancer Center
Registered studies on ClinicalTrials.gov where the overall official or a site investigator name-matches this physician, confirmed against known institution/geography. Latest few shown; the full list is part of the full profile.
Industry payments
4 companies reported payments to CMS in program years 2021 onward. These are public disclosures, not judgments. The latest:
- UROGEN PHARMA, INC.Program year20251 payment
- Incyte CorporationProgram year20251 payment
- AstraZeneca Pharmaceuticals LPProgram year20241 payment
Payment records matched to this physician's NPI in CMS Open Payments, program years 2021 onward.
NIH funding
2 NIH research awards on record, funded 2021–2025 per NIH RePORTER. The latest:
- Leveraging Radiation-Induced Senescence and PTPN2 Inhibition to Enhance Immune-Mediated Tumor Control in Rectal Cancer
Sloan-Kettering Inst Can Research
FY2025$730,398R37CA304010 - Investigating the contribution of cellular senescence to the efficacy of radiation therapy.
Sloan-Kettering Inst Can Research
FY2025$217,814K08CA255574 - Investigating the contribution of cellular senescence to the efficacy of radiation therapy.
Sloan-Kettering Inst Can Research
FY2024$255,045K08CA255574
Awards in the NIH RePORTER records where a principal investigator name matches this physician at an organization in their practice state. Latest award years shown; each row links to the project record on RePORTER.
Publications
Matched to this physician's OpenAlex author record; most-cited works shown first.
- Durable complete responses to PD-1 blockade alone in mismatch repair deficient locally advanced rectal cancer.
Journal of Clinical Oncology
2024 - Future direction of total neoadjuvant therapy for locally advanced rectal cancer
Nature Reviews Gastroenterology & Hepatology
2024
Similar KOLs
Other experts from the same institution or the same specialty.
Howard Scher, MD
Memorial Sloan Kettering Cancer Center
Robert Motzer, MD
Memorial Sloan Kettering Cancer Center
Valerie Rusch, MD
Memorial Sloan Kettering Cancer Center
Charles Sawyers, MD
Memorial Sloan Kettering Cancer Center
A basic profile from our physician directory: identity and practice contact from the federal NPPES registry, research from OpenAlex, trials from ClinicalTrials.gov, payments from CMS Open Payments — shown itemized where we have matched records, as a count where we only have a total. This person hasn't been through our full identity-adjudication pipeline yet, so funding, congress activity and public presence aren't shown. Absence of a section means “not yet looked,” never “none found.”